Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by beta-amyloid (Aβ) deposition, neurofibrillary tangles and cognitive decline. Clinical data suggests that both type 1 and type 2 diabetes are risk factors for AD-related dementia and several clinical studies have demonstrated that AD patients show alterations in peripheral glucose regulation characterized by insulin resistance (hyperinsulinemia) or hypoinsulinemia. Whether animal models of AD exhibit a pre-diabetic phenotype without additional dietary or experimental manipulation is unclear however, with contradictory data available. Further, most studies have not examined the time course of potential pre-diabetic changes relative to AD pathogenesis and cognitive decline. Thus, in this study we tested the hypothesis that a pre-diabetic phenotype (peripheral metabolic dysregulation) exists in the APP/PS1 transgenic model of AD under normal conditions and precedes AD-related pathology. Specifically, we examined glucose tolerance in male APP/PS1 mice on a C57BL/6J congenic background at 2, 4–6 and 8–9months of age by assessing fasting glucose levels, glucose tolerance, plasma insulin levels and insulin sensitivity as well as the development of pathological characteristics of AD and verified that our APP/PS1 mice develop cognitive impairment. Here we show that APP/PS1 mice, compared to wild-type controls, exhibit a significant impairment in glucose tolerance during an intraperitoneal glucose tolerance test (ipGTT) and a trend for increased fasting plasma insulin concentrations as early as 2months of age, while extracellular Aβ1–42 deposition occurs later and cognitive decline exists at 8–9months of age. Moreover, APP/PS1 mice did not respond as well to exogenous insulin as the wild-type controls during an intraperitoneal insulin tolerance test (ipITT). Taken together, these data reveal that male APP/PS1 mice on a C57BL/6J congenic background exhibit a pre-diabetic phenotype prior to the development of AD-like pathology and that this metabolic deficit persists when they exhibit neuropathology and cognitive decline. This raises the question of whether altered glucose regulation and insulin production/secretion could contribute to AD pathogenesis.

Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions

Cross-Seeding Interaction Between Β-Amyloid and Human Islet Amyloid Polypeptide.

Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.

Islet Amyloid Polypeptide Cross-Seeds Tau and Drives the Neurofibrillary Pathology in Alzheimer’s Disease

High-Fat Diet Increases Amylin Accumulation in the Hippocampus and Accelerates Brain Aging in hIAPP Transgenic Mice

Amyloid-Beta Induces Hepatic Insulin Resistance By Activating Jak2/Stat3/Socs-1 Signaling Pathway

Hyperinsulinemia-induced microglial mitochondrial dynamic and metabolic alterations lead to neuroinflammation in vivo and in vitro

Amyloid-β Induces Hepatic Insulin Resistance in Vivo Via JAK2.

Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding

Interaction of human IAPP and A<sub>1-42</sub> aggravated the AD-related pathology and impaired the cognition in mice

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Insulin Signaling in Sporadic Alzheimer's Disease.

Interaction of human IAPP and Aβ1-42 aggravated the AD-related pathology and impaired the cognition in mice

Expressions of amyloid beta peptide and its related metabolic enzymesin the brain of model mice with Alzheimer`s disease and type 2 diabetes mellitus

Glucose Tolerance and Insulin Sensitivity Are Impaired in APP/PS1 Transgenic Mice Prior to Amyloid Plaque Pathogenesis and Cognitive Decline.

High-fat diet-induced diabetes couples to Alzheimer's disease through inflammation-activated C/EBPβ/AEP pathway

Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model

Association Between Type 2 Diabetes Mellitus and Alzheimer's Disease: Common Molecular Mechanism and Therapeutic Targets

Diabetes Promotes Development of Alzheimer's Disease Through Suppression of Autophagy.

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

Early Inflammation-Associated Factors Blunt Sterol Regulatory Element-Binding Proteins-1-Mediated Lipogenesis in High-Fat Diet-Fed App(Swe)/Psen1de9 Mouse Model of Alzheimer'S Disease